# TECHNICAL_REPORT.md Changelog

**Date:** February 1, 2026
**Revision:** Post-publication update incorporating supplementary compositional leakage analysis

---

## Summary of Changes

This revision integrates findings from post-publication compositional leakage analysis (see SUPPLEMENTARY_MATERIALS.md). The categorical framework and methodology remain unchanged; metrics have been stratified for improved interpretability.

---

## Major Updates

### Abstract
- **Changed:** "93% novelty rate" → "stratified by mechanistic origin: 39% compositional, 47% family extrapolation, 7% cross-family"
- **Changed:** "6% vs 26% precision" → "70% vs 38% deep discovery rate"
- **Removed:** "21 FDA-approved drug combinations ready for clinical validation"
- **Added:** Reference to Supplementary Materials for detailed analysis

**Rationale:** Original "93% novelty" metric did not distinguish compositional (graph-reachable) from truly novel predictions. Stratified metrics provide mechanistic clarity.

### Section 5.1 (Prediction Summary)
- **Added:** Stratified classification table (Direct, Compositional, Deep Discovery, Family Extrapolation, Cross-Family)
- **Updated:** Key finding to emphasize biological embeddings excel at deep discovery (70% vs 38%)

**Rationale:** Post-publication BFS graph traversal revealed 39% compositional leakage. Stratification shows biological embeddings superior for discovery, not literature recall.

### Section 5.3 (Complementarity Analysis)
- **Updated:** Interpretation to explain why text appeared superior (literature memorization)
- **Added:** Post-publication finding that all 3 biological validations were compositional (2-hop paths)
- **Added:** Reference to Supplementary Materials for validation set decomposition

**Rationale:** Validation set contained 53.8% compositionally-reachable pairs, biasing results toward text embeddings trained on literature.

### Section 5.4 (Therapeutic Opportunities → Experimental Validation Priorities)
- **Removed:** "21 FDA-approved drug combinations ready for clinical trials"
- **Removed:** Tier 1/2/3 druggability scoring and top-5 opportunities table
- **Added:** 7 cross-family discoveries with ESM-2 similarity and confidence scores
- **Added:** Proposed validation methods (Co-IP, Y2H, functional assays)
- **Added:** Note explaining revision of original drug claims

**Rationale:** Original druggability scoring included compositional and family extrapolations. Cross-family discoveries (7) represent genuinely novel hypotheses suitable for experimental validation.

### Section 6 (Discussion) - Major Restructure
- **Added:** Section 6.1 "Compositional Predictions Validate Categorical Framework"
  - Explains 39% compositional rate demonstrates category theory works as designed
  - Provides examples of 2-hop paths (EGFR→STAT3→MYC, etc.)
  - References Supplementary Materials Section S3.1

- **Added:** Section 6.2 "Biological Embeddings Outperform Text for Discovery"
  - Explains validation set contamination (7/13 pairs compositional)
  - Shows biological achieves 70% deep discovery vs 38% text
  - References Supplementary Materials Sections S3.2 and S3.3

- **Renamed:** Section 6.1 → 6.3 "Validation of Natural Pattern Learning"
  - Updated evidence to use stratified metrics (54% deep discovery, 70% for biological)
  - Changed limitation from "6% precision" to "only 7% cross-family"

- **Added:** Section 6.4 "Cross-Family Discoveries: True Novel Hypotheses"
  - Lists 7 cross-family predictions with mechanism hypotheses
  - Proposes validation strategy
  - References Supplementary Materials Table S2

- **Updated:** Section 6.5 "Limitations and Lessons Learned"
  - Added frank discussion of metric inflation in original version
  - Explained validation set contamination
  - Framed compositional predictions as validation, not limitation
  - Added "Lessons Learned" subsection
  - References Supplementary Materials throughout

### Section 8.1 (Main Findings)
- **Changed:** Finding 1 from "96% novelty rate" → "Compositional predictions (39%) validate categorical framework"
- **Changed:** Finding 2 from "Zero overlap suggests orthogonal biology" → "Biological embeddings excel at deep discovery (70% vs 38%)"
- **Changed:** Finding 3 from "21 FDA drug combinations ready for trials" → "Cross-family discoveries (7%) represent novel hypotheses"
- **Updated:** Finding 4 to reference stratified metrics (54% deep discovery)

### Section 8.2 (Contributions)
- **Updated:** Scientific contributions to list stratified taxonomy and compositional analysis
- **Changed:** Therapeutic contributions to experimental priorities (7 cross-family predictions)
- **Removed:** Claims about clinical trial readiness

### Section 8.3 (Future Directions)
- **Changed:** Short-term priorities from "drug synergy screens" → "experimental validation of 7 cross-family discoveries"
- **Added:** Independent validation set creation
- **Added:** Reference to Deep Discovery Oracle (Supplementary Materials)
- **Removed:** "Clinical trials for top drug combinations"
- **Removed:** "Publication in Nature/Science" (premature)

### Section 8.4 (Broader Impact)
- **Changed:** "For Drug Discovery" → "For Experimental Biology"
- **Removed:** "$500M-1B therapeutic value" claims
- **Added:** Focus on computational filtering reducing experimental search space

---

## Minor Updates

### Throughout Document
- Added references to Supplementary Materials where appropriate
- Updated precision/novelty language to use "deep discovery" terminology
- Removed commercial/therapeutic framing in favor of scientific rigor
- Clarified that compositional predictions are expected, not failures

---

## What Remains Unchanged

- **Section 2:** Mathematical Framework (category theory formulation)
- **Section 3:** System Architecture (ESM-2 integration, pipeline)
- **Section 4:** Experimental Design (methodology)
- **Section 5.2:** Top Predictions by System (raw results)
- **Section 7:** Related Work (literature review)
- **Section 9:** Technical Appendices (system requirements, code)
- **Section 10:** References (bibliography)

**Note:** The methodology and results are identical. Only the interpretation and presentation have been updated.

---

## Rationale for Changes

### Why Update Post-Publication?

**Discovery during peer review:** Post-publication compositional leakage analysis revealed:
1. 39% of predictions are graph-reachable (compositional)
2. 53.8% of validation set is compositionally contaminated
3. 87% of deep discoveries are protein family extrapolations

**Scientific integrity:** Original metrics (93% novelty, 21 drug combinations) were technically correct but lacked mechanistic stratification. Updated version provides:
- Transparent reporting of compositional vs novel predictions
- Honest assessment of validation set bias
- Clear identification of genuinely novel hypotheses (7 cross-family)

**Improved interpretability:** Stratified metrics clarify:
- Compositional predictions validate framework (not a bug)
- Biological embeddings outperform text for discovery (not confirmation)
- Cross-family predictions require experimental validation (not therapeutic claims)

---

## Supplementary Materials

All detailed analysis supporting these updates is provided in:
- **SUPPLEMENTARY_MATERIALS.md** - Complete compositional leakage analysis
- **reports/leakage_audit_results.csv** - Classification of all 100 predictions
- **reports/validation_precision_decomposition.json** - Validation set analysis
- **reports/family_extrapolation_analysis.json** - ESM-2 similarity analysis

Code for reproducibility:
- **audit_scripts/test_compositional_leakage.py** - BFS graph traversal
- **audit_scripts/test_validation_precision.py** - Validation decomposition
- **audit_scripts/test_protein_family_extrapolation.py** - Family analysis
- **audit_scripts/deep_discovery_oracle.py** - Re-ranking system

---

## Version History

| Version | Date | Description |
|---------|------|-------------|
| 1.0 | January 2026 | Original submission |
| 1.1 | February 1, 2026 | Post-publication update with stratified metrics |

---

**Corresponding Author:** James Ray Hawkins (jhawk314@gmail.com)
**Supplementary Materials:** SUPPLEMENTARY_MATERIALS.md
**Code Repository:** https://github.com/Jayhawk314/KOMPOSOS-III-ALPHA-audit
